EcoDrugPlus

Cellular Tumor Antigen P53

Ensembl ID : ENSSTUG00000045335
Gene Symbol: LOC115154926
3 Cross references
160 Possible Orthologues:

Cellular Tumor Antigen P53-Like

Ensembl ID : ENSSTUG00000047410
Gene Symbol: LOC115194175
2 Cross references
227 Possible Orthologues:

Cellular Tumor Antigen P53-Like

Ensembl ID : ENSSTUG00000030959
Gene Symbol: LOC115198177
2 Cross references
226 Possible Orthologues:

Ceramide Glucosyltransferase

Ensembl ID : ENSSTUG00000015708
Gene Symbol: LOC115149531
3 Cross references
204 Possible Orthologues:

Ceramide Glucosyltransferase-Like

Ensembl ID : ENSSTUG00000018197
Gene Symbol: LOC115160183
3 Cross references
205 Possible Orthologues:

Checkpoint Kinase 1

Ensembl ID : ENSSTUG00000022460
Gene Symbol: CHEK1
3 Cross references
177 Possible Orthologues:

Cholecystokinin A Receptor

Ensembl ID : ENSSTUG00000002506
Gene Symbol: CCKAR
3 Cross references
194 Possible Orthologues:

Cholecystokinin A Receptor

Ensembl ID : ENSSTUG00000050267
Gene Symbol: CCKAR
3 Cross references
194 Possible Orthologues:

Cholecystokinin B Receptor

Ensembl ID : ENSSTUG00000008870
Gene Symbol: CCKBR
3 Cross references
185 Possible Orthologues:

Cholecystokinin B Receptor

Ensembl ID : ENSSTUG00000010130
Gene Symbol: CCKBR
3 Cross references
185 Possible Orthologues:

Cholecystokinin Receptor-Like

Ensembl ID : ENSSTUG00000003998
Gene Symbol: LOC115195121
2 Cross references
183 Possible Orthologues:

Cholecystokinin Receptor-Like

Ensembl ID : ENSSTUG00000048965
Gene Symbol: LOC115179650
3 Cross references
187 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).